Indole-based CXC chemokine receptor-2 antagonists

Abstract

Two patents claim structurally novel 4-(2-arylindol-3-yl) butanoic acid derivatives that are active as CXC chemokine receptor-2 (CXCR2) antagonists. The claimed compounds differ in the indole 5-substituent, either having a substituted phenyl ring or a nitrile group. The compounds are claimed to be useful in the treatment of a broad range of inflammatory disease.

• CXC chemokine receptor-2 (CXCR2)
• chronic obstructive pulmonary disease (COPD)
• growth-regulated oncogene-α (GRO-α)IL-8
• inflammation
• neutrophil